Peapod Lane Capital LLC trimmed its stake in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 57.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 71,418 shares of the company's stock after selling 95,425 shares during the quarter. Peapod Lane Capital LLC owned approximately 0.14% of Kodiak Sciences worth $200,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of KOD. PNC Financial Services Group Inc. lifted its position in shares of Kodiak Sciences by 1,501.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock valued at $32,000 after acquiring an additional 2,988 shares in the last quarter. US Bancorp DE purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at $40,000. Headlands Technologies LLC purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at $90,000. Vontobel Holding Ltd. acquired a new stake in shares of Kodiak Sciences in the first quarter worth $28,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Kodiak Sciences during the fourth quarter valued at $118,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.
Kodiak Sciences Price Performance
Kodiak Sciences stock traded up $0.04 during trading hours on Friday, hitting $4.53. The company had a trading volume of 278,336 shares, compared to its average volume of 346,018. The firm has a market capitalization of $239.00 million, a P/E ratio of -1.25 and a beta of 2.28. The firm's fifty day moving average is $3.83 and its 200-day moving average is $4.60. Kodiak Sciences Inc. has a fifty-two week low of $1.92 and a fifty-two week high of $11.60.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.20). Analysts anticipate that Kodiak Sciences Inc. will post -3.45 earnings per share for the current year.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "neutral" rating and issued a $3.00 price objective on shares of Kodiak Sciences in a research note on Monday, March 31st.
Get Our Latest Report on Kodiak Sciences
About Kodiak Sciences
(
Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
See Also
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
